Lilly Asian Ventures makes venture capital investments in Asia for Eli Lilly and Company, a global innovation-driven pharmaceutical company. Lilly Asian Ventures invests in promising life science companies with strong management teams and innovative technology and/or business models. Their initial focus will be primarily on opportunities in China, although they will consider investment opportunities elsewhere in east and south Asia.

Lilly Asia Ventures

Eight Roads Ventures is a global venture capital firm managing $11bn of assets across offices in the UK, China, India, Japan, and the US. Together with our associated funds, including our US sister fund F-Prime Capital, our 50-year history of investing includes partnerships with over 500 companies such as Alibaba, AppsFlyer, Chewy, Fareye, Fever, Flywire, Fireblocks, Funnel.io, Gloat, Hibob, Icertis, Neo4j, Otrium, Owkin, Paidy, Spendesk, Tibber, Toast, Wallapop and Xoom.

Eight Roads Ventures

F-Prime's roots are in one of America’s great entrepreneurial success stories. Fidelity Investments was founded in 1946 and grew from a single mutual fund into one of the largest asset management firms in the world, with over $2 trillion in assets under management. For the last forty years, this venture capital group has had the privilege of backing other great entrepreneurs as they built ground-breaking companies in technology and life sciences, including Atari, MCI, ROLM Corp., Alibaba, Ironwood Pharmaceuticals, and Ultragenyx.  Today, F-Prime's funds are larger and more global, but its teams are still small and local. F-Prime stays true to its entrepreneurial roots. In the US and Europe, F-Prime Capital Partners is investing in healthcare (formerly Fidelity Biosciences) and in technology (formerly part of Devonshire Investors). In other geographies, its sister fund is called Eight Roads (formerly Fidelity Growth Partners), with investment teams in London, Shanghai, Beijing, Hong Kong, Tokyo, and Mumbai.   Together F-Prime brings a world of insight, domain expertise and relationships to support entrepreneurs. Without the pressure of fundraising from outside investors, F-Prime Capital Partners focuses all of its time finding and helping great entrepreneurs build important companies.

F-Prime Capital

Legend Capital, a subsidiary of Legend Holdings Ltd., started its vintage year in April, 2001 with a mission to become a top-notch and the most respected venture capital investment manager in China.  Managing up to US$700 million across four funds, Legend Capital focuses on driving high-growth ventures with operations substantially based in China or on markets related to China.  Legend Capital mainly invests in early stage IT companies, specifically, in sectors of network applications and services, outsourcing and professional services, Infrastructure (IC design/key components), and mid-market growth stage companies in the fields of consumer goods, clean technology, health care, equipment manufacturing and modern services.  Among over 60 portfolio companies are Joyo.com (acquired by Amazon.com), SinoCom (0299.HK), Solarfun Power (Nasdaq: SOLF), Spreadtrum Communications (Nasdaq: SPRD), China Sunshine Paper (2002.HK), and VanceInfo (NYSE:VIT), Eyang (0117.HK), etc.  As an active investor, Legend Capital provides its portfolio companies extensive business resources and tailored services to assist with business development, company image building, and other critical company building activities on Chinese market so as to add value and maximize returns. Legend Capital is proud and thankful that it has the opportunity to blaze a trail with its innovative practice for China's venture capital industry.

Legend Capital

Temasek Holdings is a lender provider. The company offers debt financing and focuses on transforming economies, increasing middle-income populations, developing comparative advantages, and emerging champions. Financial services, transportation, industrial, consumer, real estate, telecommunications, media, technology, and life sciences are among the industries served by the firm.

Temasek Holdings

Founded in 2005, Hillhouse is a leading global investment management firm, active across public equity, private equity, real estate and private credit. The firm invests over a long-term horizon and partners with exceptional entrepreneurs to deliver sustainable value creation for quality companies. Hillhouse is a full life-cycle private equity firm, investing for the long term across opportunities in the healthcare, business services, consumer, and industrials sectors. The firm manages capital on behalf of global institutions such as non-profit foundations, endowments, and pensions.

Hillhouse Investment

###Frontline BioVentures merged with WuXi Healthcare Ventures to form 6 Dimensions Capital### Frontline BioVentures is a premier China-based venture capital firm specialize in the investment of innovative life science companies We focus on business within strategic life science and technology areas promoted by the Chinese government. Currently we manage two funds, a RMB denominated fund and a parallel USD fund, which offers structural flexibilities to best serve the needs of portfolio companies.

Frontline BioVentures

SDIC Fund Management is a private equity that manages funds and raises nearly 60 billion yuan at present.  The management funds cover financial institutions, social security funds, state-owned and private capital, and it is one of the largest professional private equity management institutions in China.

SDIC Fund Management

Ping An Ventures is a professional VC under Ping An Insurance (Group) Company of China, Ltd. with focused interest in start-ups of emerging innovation. It is committed to growing with the partners and driving success by provision of both funds and managerial expertise, resources and a platform.''

Ping An Ventures

Taikang Insurance Group was established in 1996 and is headquartered in Beijing. It has developed into a large insurance financial service group covering insurance, asset management, and medical care. Taikang Insurance Group owns Taikang Life Insurance, Taikang Assets, Taikang Pension, Taikang Jiantou, Taikang Health, Taikang Online, and other subsidiaries. The business scope covers a wide range of areas including life insurance, Internet property insurance, enterprise annuity, asset management, medical pension, health management, and commercial real estate. As of the end of 2017, the assets under management exceeded RMB 1.2 trillion. Since its establishment 22 years ago, the Group has provided a total of 225 million customer service customers and over 340,000 service enterprise customers. The accumulated payment of claims amounted to 35.1 billion yuan and accumulated tax payment of 37.5 billion yuan. It has been ranked among the “Top 500 Chinese Enterprises” for 14 consecutive years. In 2018, Taikang Insurance Group ranked No. 489 in the Fortune Global 500 list with an operating income of US$24.085 billion, marking Taikang's entry into the ranks of the world's largest insurance financial services group. Taikang Insurance Group has always adhered to the concept of “professionalization, marketization, and standardization”, and has deepened the life insurance industry chain. Through 3,900 offline physical networks, online internet platforms and 700,000 employees and salesmen across the country, relying on “vigorous pension, The four-in-one business model of high-end medical care, excellent financial management, and ultimate care builds a healthy ecosystem of the big health industry. Committed to becoming the world's leading insurance financial services group, making insurance more secure, more convenient and more affordable, making people healthier, longer life and richer, making Taikang a part of people's happy life. Taikang Insurance Group integrates the whole life industry chain through the cross-border integration of virtual insurance products and physical medical services to implement a healthy China strategy. As the first pilot enterprise in China's insurance industry to invest in old-age care communities, the Group has completed the layout of pension communities in key cities such as Beijing, Shanghai, Guangzhou, Sanya, Suzhou, Chengdu, Wuhan, Hangzhou, Nanchang, Xiamen, Shenyang and Changsha, becoming the largest in the country. One of the high quality chain pension groups. Adhering to the concept of medical integration, the rehabilitation community with rehabilitation and geriatrics is built in the old-age community to build a Taikang international standard rehabilitation system. At present, the Group has invested in the operation of Taikang Xianlin Drum Tower Hospital, the construction of Taikang Tongji (Wuhan) Hospital, the launch of Taikang Southwest Medical Center, and efforts to build a number of medical education and research integrated medical centers. Taikang Insurance Group adheres to the concept of “serving the public and giving back to the society” and actively fulfills its corporate social responsibility. Especially in the fields of education and academics, a comprehensive education donation system has been formed from primary schools, middle schools, universities to China's economic theory innovation awards. Through the non-profit art organization “Tai Kang Space”, it sponsored and supported the development and research of Chinese contemporary art, and launched “Yi Cai”. The Public Welfare Program continues to support life and big health charity initiatives, and we donate to the nursing homes throughout the country to let more elderly people enjoy their happy and happy years. At present, the personal donation amount of the group and Chairman Chen Dongsheng has reached 430 million yuan.

Taikang Insurance Group

China Life Investment Holding is an investment platform for China Life’s magnificent vision in healthcare sector, focusing on investment opportunities of premiu-quality companies along the industry chain of healthcare. It is committed to give full play to the driving role of commercial insurance, and deeply promote the integration and development of healthcare and insurance service, so as to meet diversified medical service and insurance protection demands of customers. Leveraging China Life’s massive resources, the Company can enrich portfolio companies’ customer base and provide insurance solutions integrally hence accelerating developments of portfolio companies. In addition, through cooperation and collaboration with portfolio companies, China Life can better serve its customers with premium-quality, convenient and integrated insurance, healthcare and medical solutions, and make a contribution to healthcare industry’s development and evolvement in China.

China Life Investment Holding

Milestone

Founded in 1992, Capital Group Private Markets has invested over $5 billion in more than 80 companies across global emerging markets from its six emerging markets private equity funds. Capital Group Private Markets is an experienced leader in emerging markets private equity and a pioneer of the global approach to building a diversified emerging markets portfolio. As an active investor across Latin America, Capital Group Private Markets has been investing in Colombia for over 15 years.

Capital Group Private Markets

Ally Bridge Group is a healthcare-focused investment group committed to venture and growth capital, buyout, and hedge fund investing. Ally Bridge Group focuses on both private and public equity investments, with a particular emphasis on pioneering life sciences companies and technologies. The firm is dedicated to bridging the gap between groundbreaking healthcare innovations and global markets. By leveraging its expertise and extensive network, Ally Bridge Group supports the growth and development of its portfolio companies. Its investment strategy is centered on transformative technologies and solutions that address major unmet medical needs.

Ally Bridge Group

Rock Springs Capital is an investment company situated in Baltimore, Maryland. The company specializes in offering advisory services, primarily focused on managing security portfolios and providing portfolio management solutions to businesses and institutional clients. Through its advisory activities, Rock Springs Capital aims to assist clients in optimizing their investment strategies and achieving their financial goals.

Rock Springs Capital

Cormorant Asset Management is an employee-owned hedge fund sponsor that provides its services to pooled investment vehicles. The firm also focuses on both public and private market innovative companies in the biotechnology and life sciences marketplace.

Cormorant Asset Management

Innovent Biologics

IASO Biotherapeutics (IASO BIO) is a Nanjing-based biopharmaceutical company focused on the discovery, development and commercialization of cell therapies in the field of oncology.

AnHeart Therapeutics is a developer of innovative pharmaceutical products. The company is focused on acquiring, developing and commercializing innovative pharmaceutical products that improve human health and quality of life. It's main research product, AB-106, is an oral, highly selective ROS1/NTRK small molecule inhibitor.

Innovent Biologics, Inc. is a privately held biopharmaceutical company dedicated to developing and manufacturing monoclonal antibodies to be marketed in China and elsewhere around the world. Innovent is funded by Fidelity's venture arm, a prominent investment firm in the US, Lilly Ventures, and Suzhou bioBay.  The registered capital is 30 million US Dollars. The founders and senior management team of Innovent have over 70 years of combined work experience in the discovery, development, and manufacture of biologics in the US, Europe, and worldwide and were involved in the launch of such products as Bexxar, Conbercept, Natrecor, Oncorine, Recombivax HB, and others.

Innovent Biologics, Inc. is a world-class biopharmaceutical company founded in 2011 that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major diseases. The company has built a robust pipeline of 36 valuable assets, including 22 in oncology. As of 2024, Innovent has launched 10 products in the market, including TYVYT (sintilimab injection), BYVASDA (bevacizumab biosimilar injection), SULINNO (adalimumab biosimilar injection), HALPRYZA (rituximab biosimilar injection), PEMAZYRE (pemigatinib oral inhibitor), olverembatinib, CYRAMZA (ramucirumab injection), Retsevmo (selpercatinib capsules), FUCASO (equecabtagene autoleucel injection) and SINTBILO (tafolecimab injection). The company has four new drug applications under regulatory review, five assets in Phase III or pivotal clinical trials, and 18 more molecules in early clinical stage. Innovent's research and development strategy is centered on global innovation, with a focus on the "IO + ADC" approach in oncology. The company has established manufacturing facilities in Suzhou and Hangzhou, with a total antibody production capacity of 230,000L. In 2023, Innovent reported total revenue of RMB6,206.1 million, an increase of 36.2% compared to 2022.

Innovent and Xuanzhu Enter into Clinical Trial Collaboration Investigating Combination Therapy of Sintilimab (PD

Innovent and IASO Bio Enhance Strategic Collaboration in Cell Therapy

Innovent and WeComput Announce Strategic Partnership to Advance AI-Driven Drug Discovery and Development

Innovent Reports Oncology Pipeline Updates at Investor Meeting

Innovent Announces the Second Phase 3 Trial of Mazdutide in Chinese Patients with Type 2 Diabetes Met Study Endpoints, and Plans to Submit NDA of Mazdutide to the NMPA

Innovent Announces 2023 Annual Results and Business Updates

Innovent Biologics and Sanofi Enter Strategic Collaboration to Accelerate Development of Oncology Medicines and Expand Presence in China

Top 3 Stocks Estimated To Be Undervalued On SEHK In July 2024

Bringing Life-Saving Biologics to More Patients

Biosimilars

Innovent Biologics is a leading biopharmaceutical company founded in 2011 with the mission to develop and commercialize innovative and affordable medicines. The company focuses on oncology, cardiovascular and metabolic diseases, autoimmune disorders, and ophthalmology. As of March 2024, Innovent has ten approved products in the Chinese market, including TYVYT (sintilimab injection), BYVASDA (bevacizumab injection), SULINNO (adalimumab injection), and others. The company's core product, TYVYT, is an anti-PD-1 monoclonal antibody approved across seven indications, making it the most widely approved PD-1 inhibitor in China.

Innovent to Present Preclinical Data of Multiple Novel Molecules at the 2024 AACR Annual Meeting

IBI-363 by Innovent Biologics for Solid Tumor: Likelihood of Approval

IBI-130 by Innovent Biologics for Solid Tumor: Likelihood of Approval

IBI-3002 by Innovent Biologics for Asthma: Likelihood of Approval

Innovent released the results of two clinical studies of IBI311 (an anti-IGF-1R monoclonal antibody) in oral presentations at the Asia-Pacific Academy of Ophthalmology Congress and International Congr

Targeting complex diseases with complex molecules

Large-molecule Therapeutics

Innovent Biologics, WeComput to jointly advance AI-driven drug discovery and development

IASO Biotherapeutics

Sanofi

To bring innovative medicines to patients in China with difficult-to-treat cancersT

Companies that develop large molecules that combine the targeting ability of monoclonal antibodies with the cytotoxic effects of chemotherapy drugs

AnHeart Therapeutics

Octagon Capital Advisors

Cenova

Sage Partners

Laurion Capital Management

Eli Lilly

Eli Lilly and Innovent Biologics have expanded their strategic alliance for TYVYT, an anti-PD-1 monoclonal antibody used in immuno-oncology, initially developed for the Chinese market.

Companies that develop engineered proteins that can target specific proteins or cells in the body

Innovent Biologics, Inc. is a world-class biopharmaceutical company founded in 2011 that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major diseases. The company has built a robust pipeline of 36 valuable assets, including 22 in oncology. As of 2024, Innovent has launched 10 products in the market, including TYVYT (sintilimab injection), BYVASDA (bevacizumab biosimilar injection), SULINNO (adalimumab biosimilar injection), HALPRYZA (rituximab biosimilar injection), PEMAZYRE (pemigatinib oral inhibitor), olverembatinib, CYRAMZA (ramucirumab injection), Retsevmo (selpercatinib capsules), FUCASO (equecabtagene autoleucel injection) and SINTBILO (tafolecimab injection). The company has four new drug applications under regulatory review, five assets in Phase III or pivotal clinical trials, and 18 more molecules in early clinical stage. Innovent's research and development strategy is centered on global innovation, with a focus on the "IO + ADC" approach in oncology. The company has established manufacturing facilities in Suzhou and Hangzhou, with a total antibody production capacity of 230,000L. In 2023, Innovent reported total revenue of RMB6,206.1 million, an increase of 36.2% compared to 2022.

Coherus BioSciences is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative immunotherapies for cancer treatment. The company's strategy revolves around building a leading immuno-oncology franchise funded by cash generated from its portfolio of FDA-approved therapeutics. Coherus markets several biosimilar products in the US, including UDENYCA (pegfilgrastim-cbqv), a biosimilar of Neulasta, CIMERLI (ranibizumab-eqrn), a biosimilar of Lucentis, and YUSIMRY (adalimumab-aqvh), a biosimilar of Humira.
In July 2023, Coherus launched YUSIMRY at a list price of USD 995 per carton for two 40 mg/0.8 mL autoinjectors, representing a discount of more than 85% compared to Humira. This pricing strategy aims to improve patient access to adalimumab treatment by offering significant cost savings. YUSIMRY is indicated for various autoimmune conditions, including rheumatoid arthritis, psoriatic arthritis, and Crohn's disease.
Coherus is also developing toripalimab, an anti-PD-1 antibody, for the US and Canadian markets through a licensing agreement with Shanghai Junshi Biosciences Ltd. A Biologics License Application (BLA) for toripalimab in combination with chemotherapy for treating recurrent or metastatic nasopharyngeal carcinoma was under FDA review.
In March 2024, Coherus reported net revenue of USD 91.5 million for Q4 2023 and USD 257.2 million for the full year 2023, driven by sales of UDENYCA and CIMERLI. However, the company faced challenges, including a net loss of USD 79.7 million in Q4 and USD 237.9 million for the full year 2023. To address these challenges, Coherus initiated a workforce reduction of 30% to streamline operations and focus on oncology.

Coherus Biosciences

Custom Biologics is a Canadian contract research organization (CRO) specializing in bioanalytical services for biopharmaceuticals, vaccines, and cell and gene therapy products. With over 20 years of experience, the company focuses on designing and validating regulatory compliant assays for functional characterization, potency/bioactivity assessments, clinical pharmacokinetics, and immunogenicity of biotherapeutic drugs. Custom Biologics' genomics group develops molecular genetic assays for gene and genome analysis, measuring genetic inserts and transgenes in gene therapy vectors, oncolytic viruses, and nucleic acid-based vaccines. The company has also developed a proprietary isothermal nucleic acid amplification technology called DASL-RAPID for rapid identification of human and food-borne pathogens. Custom Biologics maintains a Health Canada cGMP Drug Establishment License and operates under a quality system based on FDA and EMEA GLP guidelines. The company's services are utilized in preclinical research and development programs, as well as for validated GMP-compliant assays suitable for stability analysis, clinical analysis, and clinical/market lot release testing. Custom Biologics employs state-of-the-art bioanalytical laboratory equipment and sophisticated statistical software to generate data for submissions to regulatory agencies worldwide.

Custom Biologics

CuriRx, Inc., founded in 2012, is a contract development and manufacturing organization (CDMO) based in Wilmington, Massachusetts. The company specializes in providing end-to-end support for biotherapeutic drug developers, focusing on complex molecules such as recombinant proteins, monoclonal antibodies, bispecific antibodies, vaccines, antibody drug conjugates, oligonucleotides, and gene therapy products. CuriRx's services encompass upstream and downstream process development, optimization, characterization, scale-up and scale-down, analytical development, formulation development, and lyophilization.
In January 2022, CuriRx launched its Advanced Bioprocessing and Analytical Center, which combines state-of-the-art bioprocessing laboratories with the CuriLytics Platform's high-resolution analytical instrumentation. This center aims to accelerate biotherapeutic drug development by leveraging the team's extensive bioprocessing experience and employing the latest methods in upstream and downstream process development. The CuriLytics Platform utilizes high-resolution mass spectrometry and various orthogonal characterization methods to further de-risk drug development.
CuriRx has the capacity to produce non-GMP vials for animal studies and non-GMP stability support studies. The company's key personnel have been involved in successful development projects for notable drugs such as HUMIRA, SYNAGIS, BLINCYTO, and GATTEX. In September 2013, CuriRx was awarded a five-year contract by the National Cancer Institute for the development and production of oncology products, demonstrating its expertise in the field.

CuriRx

Paras Biopharmaceuticals Finland Oy is a biopharmaceutical technology development company based in Oulu, Finland. Founded in 2012, the company specializes in the development and manufacturing of complex biologics and biosimilars using microbial expression systems. Paras Biopharmaceuticals operates a state-of-the-art 25,000 square foot biologics production facility in Finland, which includes 4,300 square feet of classified cleanroom space. The facility is equipped for media and buffer preparation, fermentation, harvest and extraction, purification, final filtration, and freeze-drying.
The company's core activities are divided into two main divisions: Paras Biopharma, which focuses on biologics Contract Development and Manufacturing Organization (CDMO) services, and Paras Biologics, which handles biosimilar development and licensing. Paras Biopharmaceuticals has developed proprietary technology platforms including Biomultifold, Noblecleav, and Cytofold StructQuant to achieve high productivity and quality in biologics manufacturing. These technologies enable the company to produce complex proteins and biosimilars cost-effectively at scale.
As of December 2022, Paras Biopharmaceuticals reported achieving success with "Continuous Biomanufacturing" for high-value onco-immunology and urology biosimilars. The company has also made advancements in maximizing recombinant protein expression in microbial systems, reporting expression levels of up to 12g/L or more of fully folded, biologically active protein in fermentation broth as of July 2023.

Paras Biopharmaceuticals

Kashiv Biosciences, LLC is a fully integrated biopharmaceutical company focused on developing biosimilars and specialty biopharmaceutical products. The company has global research and development, clinical, regulatory, and manufacturing capabilities. Kashiv utilizes its MayaBio reactor technology to develop biosimilars. The company's product portfolio includes biosimilars targeting conditions such as asthma, chronic idiopathic urticaria, and neutropenia. Kashiv's lead biosimilar candidate, ADL018, is a proposed biosimilar to Xolair (omalizumab) currently in Phase III clinical trials for chronic spontaneous urticaria. In March 2022, Kashiv received FDA approval for its first biosimilar RELEUKO (filgrastim-ayow), a biosimilar referencing Neupogen. The company has a robust pipeline of seven biosimilars and multiple 505(b)(2) and complex peptide generic products in development. Kashiv operates FDA-approved GMP manufacturing facilities in Chicago, Illinois and has state-of-the-art R&D infrastructure in Ahmedabad, India. The company is headquartered in Piscataway, New Jersey.
Key customers and partnerships
Kashiv has established strategic partnerships to commercialize its products globally. In October 2023, Kashiv entered into an exclusive licensing agreement with Alvotech for the development and commercialization of ADL018 in Europe, the UK, Australia, Canada, and New Zealand. In July 2024, Kashiv signed an exclusive licensing agreement with Amneal Pharmaceuticals for the commercialization of ADL018 in the US. Kashiv has also collaborated with Amneal on the development and commercialization of other biosimilars, including RELEUKO and FYLNETRA. These partnerships allow Kashiv to leverage its partners' commercial expertise and global reach to bring its biosimilar products to market.

Kashiv Biosciences

Biotechnology companies that focus on the research, development, production, and commercialization of prescription drugs including biosimilars.

Biotechnology companies that focus on the research, development, production, and commercialization of biosimilars based on original biological medicine.

Companies offering R&D capabilities and production facilities to biosimilar companies on contracts or partnerships.

Biopharmaceutical technology development and support service companies that offer specialized solutions to biosimilar companies.

Companies offering testing solutions to support the biological characterization, comparability, and other clinical assessments required in the biosimilar development process.

AI/ML-driven technology platforms support drug design and development process and integration of drug substance development

Innovent Biologics is a leading biopharmaceutical company founded in 2011 with the mission to develop and commercialize innovative and affordable medicines. The company focuses on oncology, cardiovascular and metabolic diseases, autoimmune disorders, and ophthalmology. As of March 2024, Innovent has ten approved products in the Chinese market, including TYVYT (sintilimab injection), BYVASDA (bevacizumab injection), SULINNO (adalimumab injection), and others. The company's core product, TYVYT, is an anti-PD-1 monoclonal antibody approved across seven indications, making it the most widely approved PD-1 inhibitor in China.
Innovent has a robust pipeline with three new drug applications under review, four assets in Phase III or pivotal trials, and 19 molecules in early clinical development. The company's innovative pipeline spans various modalities, including bispecific antibodies, antibody-drug conjugates (ADCs), and RNA therapeutics. In oncology, Innovent is advancing the next-generation immunotherapy combinations with ADCs, such as the CLDN18.2 ADC (IBI343) and the EGFR/B7H3 bispecific ADC (IBI3001). The company's metabolic pipeline includes mazdutide, a first-in-class GLP-1R/GCGR dual agonist in late-stage development for weight management.
Innovent has a strong emphasis on global innovation, with its Innovent Academy delivering eight novel molecules into IND-enabling stage in 2023. The company has established large-scale manufacturing facilities in Suzhou and Hangzhou to support global supply. Innovent collaborates with over 30 global healthcare leaders, reinforcing its commitment to advancing biopharmaceutical innovation worldwide.

<div>
 
 ADC Therapeutics is a clinical-stage biotechnology company focused on developing and commercializing next-generation antibody-drug conjugates (ADCs) for treating cancer. The company's ADCs leverage highly potent and targeted pyrrolobenzodiazepine (PBD) dimer technology, which causes the ADCs' antibodies to bind to specific tumor cell surface antigens. Once internalized, the potent PBD dimer is released inside the cell, creating covalent cross-links between the DNA strands, disrupting cell division without triggering DNA repair mechanisms.
 
 
 
 
 ADC Therapeutics' lead product candidate, Zynlonta, received FDA approval in April 2021 for treating adult patients with relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. The company is also advancing a deep pipeline of other PBD-based ADCs targeting hematologic malignancies and solid tumors. As of May 2021, ADC Therapeutics reported revenues of USD 38.2 million, reflecting initial sales of Zynlonta.
 
 
 
 
 In March 2022, ADC Therapeutics acquired US commercial rights to Overrkey Biological's anti-HER2 ADC Overena, broadening its cancer treatment portfolio. The acquisition aligned with the company's strategic focus on expanding globally with its PBD-based ADC technology.
 
</div>

ADC Therapeutics

Sirnaomics is a biopharmaceutical company engaged in the discovery and development of RNA therapeutics. The company focuses on innovative drugs for indications with unmet medical needs and large market opportunities. Sirnaomics utilizes two proprietary delivery platforms: the Polypeptide Nanoparticle Formulation (PNP) and the second generation of GalNAc conjugates called GalAhead.
Sirnaomics has established a robust pipeline of drug candidates, with several products in clinical and preclinical stages. The company's lead clinical product, STP705, has demonstrated positive results in Phase II clinical trials for the treatment of squamous cell carcinoma in situ (isSCC) and basal cell carcinoma (BCC). Additionally, STP705 is being explored for focal fat reduction in the medical aesthetics field. Another promising candidate, STP707, is a PNP formulation consisting of two siRNAs targeting TGF-β1 and COX-2 for intravenous treatment of solid tumors. STP707 has shown promising results in a Phase I basket clinical study, exhibiting stable disease response in 74% of evaluable patients.
Sirnaomics achieved a significant milestone by advancing STP122G, the first candidate utilizing the GalAhead technology, into clinical development. STP122G targets Factor XI for anticoagulation therapeutics and is currently undergoing Phase I clinical trials.
In March 2023, Sirnaomics' subsidiary, RNAimmune, received IND clearance from the FDA to initiate a Phase I clinical trial for RV-1770, an mRNA vaccine targeting respiratory syncytial virus (RSV). Additionally, RNAimmune obtained FDA clearance for a SARS-CoV-2 vaccine booster candidate, RV-1730.
Sirnaomics has established its manufacturing facility in China, enabling the transition from a biotech company to a biopharmaceutical corporation. The facility has successfully produced a full GMP batch of STP707 for human injection and is expected to support the company's clinical pipeline.
In July 2024, Sirnaomics announced the completion of IND-enabling studies for STP125G, an siRNA therapeutic targeting Apolipoprotein C3 (ApoC3) for the treatment of cardiovascular diseases. The positive results from non-human primate studies support the filing of an IND with the FDA.

Sirnaomics

Sesen Bio is a late-stage clinical company that previously focused on developing targeted fusion protein therapeutics for cancer treatment. Its lead product candidate, Vicineum, is a locally administered targeted fusion protein composed of an anti-epithelial cell adhesion molecule (EpCAM) antibody fragment tethered to a truncated form of Pseudomonas exotoxin A for the treatment of non-muscle invasive bladder cancer (NMIBC).
In February 2021, the FDA accepted Sesen Bio's Biologics License Application (BLA) for Vicineum to treat BCG-unresponsive NMIBC, granting Priority Review. However, in August 2021, the company received a Complete Response Letter from the FDA, requiring an additional Phase 3 clinical trial for potential resubmission. Following discussions with the FDA in March 2022, Sesen Bio aligned on most elements for the trial design and planned to meet again in mid-2022 to finalize outstanding items.
On July 15, 2022, Sesen Bio made the strategic decision to voluntarily pause further development of Vicineum in the US due to the incremental timeline and costs associated with the additional Phase 3 trial. The company shifted its primary focus to consummating a strategic transaction to maximize shareholder value while seeking a partner for Vicineum's further development.
In September 2022, Sesen Bio announced a pending merger with Carisma Therapeutics, a clinical-stage biopharmaceutical company developing immunotherapies based on engineered macrophages. This merger was approved by Sesen Bio's stockholders in March 2023, with the combined company operating under the name Carisma Therapeutics Inc. and trading on the Nasdaq under the ticker "CARM".
Upon closing the merger in March 2023, Sesen Bio declared a special cash dividend of USD 75 million (around USD 0.36 per share) to its stockholders and issued them Contingent Value Rights (CVRs) entitling them to potential proceeds from the sale of Vicineum and other assets, as well as a USD 30 million milestone payment under the Roche Asset Purchase Agreement.

Sesen Bio

ACELYRIN, INC. is a late-stage clinical biopharmaceutical company focused on developing transformative medicines for immunology and inflammatory diseases. The company's lead product candidate is izokibep, a next-generation inhibitor of interleukin-17A (IL-17A) designed to overcome limitations of monoclonal antibodies. Izokibep is being evaluated in multiple late-stage trials for moderate-to-severe hidradenitis suppurativa (HS), psoriatic arthritis (PsA), and noninfectious uveitis.
In March 2024, ACELYRIN reported positive top line data from a global Phase 2 billion/3 clinical trial of izokibep in PsA, meeting the primary endpoint of ACR50 at 16 weeks with high statistical significance. The trial also demonstrated robust clinical responses for higher hurdle endpoints like ACR70, PASI100, and composite measures, indicating izokibep's potential to provide clinically meaningful benefits. Additionally, ACELYRIN announced differentiated long-term 32-week data from a global Phase 2 billion trial of izokibep in HS, showing rapid, dose-ordered improvement across multiple disease manifestations, including HiSCR100 achieved earlier than reported by other IL-17 inhibitors.
ACELYRIN's other late-stage asset is lonigutamab, a subcutaneously delivered monoclonal antibody targeting IGF-1R being investigated for the treatment of thyroid eye disease (TED). In March 2024, ACELYRIN announced positive proof-of-concept data from a Phase 1/2 trial, demonstrating rapid improvements in proptosis and clinical activity score within three weeks after the first dose.
As of December 31, 2023, ACELYRIN had cash, cash equivalents, and short-term marketable securities totaling USD 721.3 million, providing a runway to support key late-stage data milestones and registrational studies across multiple indications. In January 2023, ACELYRIN acquired ValenzaBio, adding lonigutamab and other immunology assets to its pipeline.

ACELYRIN

Companies that develop large molecules that can be used to target specific RNA molecules in the body, either to silence or replace them

Companies that develop large molecules that can be used to replace or supplement deficient or malfunctioning proteins in the body

Companies specializing in peptide-based treatments leverage short amino acid chains, known as peptides, to target and modulate various biological processes for therapeutic applications

AL/ML used to identify potential drug targets, and support protein engineering and optimization

Artificial intelligence is identifying and testing new therapies faster than ever.

AI Drug Discovery

PROMINENT_CATEGORY

<div>
 
 Chinese biopharmaceutical firm Innovent Biologics has formed a partnership with artificial intelligence company WeComput. They intend to improve Innovent's AI for Drug Discovery platform, although the specifics of the agreement and any financial details are not disclosed.
 The collaboration's goal is to enhance Innovent's research and development process for drug discovery, utilizing WeComput's WeMol molecular design platform. This partnership could potentially lead to cost reduction, the acceleration of the R&amp;D cycle, and an increase in success rates.
 Innovent Biologics, which is based in China, specializes in the development, production, and commercialization of monoclonal antibodies for broader population access. They offer products in various therapeutic areas such as oncology, autoimmune diseases, cardiovascular and metabolic diseases, and ophthalmology. Their leading product, TYVYT, is a PD-1 inhibitor created with Eli Lilly and is used in a range of cancer treatments.
 
</div>

Innovent Biologics

Sources

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless